The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mantle cell lymphoma
FollowWhat is new in Mantle cell lymphoma research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AcalabrutinibPhase 3 · NCT06564038 · NCT05495464 · NCT04662255 · NCT04566887 · NCT03932331 · NCT06054776 · NCT04115631 · NCT07910435 · NCT04626791 · NCT02972840 · NCT07377578 · NCT05004064 · NCT05951959 · NCT04484012 · NCT03946878 · NCT03863184 · NCT06846489 · NCT04883437 · NCT04189757 · NCT04783415 · NCT04765111 · NCT04855695
- Autologous Hematopoietic Stem Cell TransplantationPhase 3 · NCT02797470 · NCT01318317 · NCT03267433 · NCT01815749 · NCT05432635
- bendamustinePhase 3 · NCT04002297 · NCT03872180 · NCT06496308 · NCT06191887 · NCT06854003 · NCT01415752 · NCT04223765 · NCT04115631 · NCT02972840 · NCT01661881 · NCT04792489 · NCT06084936
- Bendamustine InjectionPhase 3 · NCT06363994
- Biospecimen CollectionPhase 3 · NCT06572618 · NCT06191887 · NCT06675123 · NCT07444710 · NCT06252675 · NCT05976763 · NCT07892027 · NCT06054776 · NCT06859008 · NCT07910435 · NCT03267433 · NCT07003295 · NCT06839053 · NCT04195633 · NCT01955499 · NCT05861050 · NCT06357676 · NCT05910801 · NCT07578077
- Bone Marrow AspiratePhase 3 · NCT03267433
- Bone Marrow BiopsyPhase 3 · NCT06572618 · NCT06675123 · NCT06252675 · NCT05976763 · NCT06054776 · NCT06859008 · NCT07910435 · NCT03267433 · NCT06839053 · NCT04195633 · NCT01955499 · NCT05861050 · NCT06357676 · NCT05910801 · NCT07578077
- ColonoscopyPhase 3 · NCT05976763
- Computed TomographyPhase 3 · NCT06191887 · NCT06675123 · NCT07444710 · NCT05976763 · NCT07892027 · NCT06054776 · NCT06859008 · NCT03267433 · NCT07003295 · NCT06839053 · NCT04195633 · NCT01955499 · NCT05861050 · NCT06357676 · NCT05910801 · NCT07578077
- EsophagogastroduodenoscopyPhase 3 · NCT05976763
- GlofitamabPhase 3 · NCT07460362 · NCT06192888 · NCT07444710 · NCT06252675 · NCT06054776 · NCT05833763 · NCT07748364 · NCT06558604 · NCT07003295 · NCT07453095 · NCT06084936 · NCT05861050 · NCT06656221 · NCT06357676
- IbrutinibPhase 3 · NCT03479268 · NCT02427620 · NCT02682641 · NCT01804686 · NCT02159755 · NCT04662255 · NCT07377578 · NCT03478514 · NCT03710772 · NCT03153202 · NCT05864742 · NCT03282396 · NCT01880567 · NCT02446236 · NCT05283720 · NCT06482684 · NCT01955499 · NCT06357676
- ICP-248Phase 3 · NCT07784101 · NCT07082686
- LenalidomidePhase 3 · NCT07261163 · NCT07460362 · NCT06192888 · NCT01415752 · NCT03523975 · NCT03863184 · NCT05025800 · NCT06504199 · NCT02446236 · NCT05283720 · NCT06084936 · NCT01955499 · NCT05861050 · NCT05910801
- Magnetic Resonance ImagingPhase 3 · NCT06191887 · NCT05976763 · NCT06859008 · NCT01955499 · NCT06357676 · NCT05910801
- ObinutuzumabPhase 3 · NCT03872180 · NCT07261163 · NCT06192888 · NCT06252675 · NCT06054776 · NCT05833763 · NCT03863184 · NCT06558604 · NCT07719556 · NCT06504199 · NCT07003295 · NCT04883437 · NCT07799220 · NCT03824483 · NCT04855695 · NCT06084936 · NCT05861050 · NCT06656221 · NCT06357676
- OrelabrutinibPhase 3 · NCT07784101 · NCT06496308 · NCT07199296 · NCT07377578 · NCT07272499 · NCT07719556 · NCT06363994 · NCT06656221
- Orelabrutinib PlaceboPhase 3 · NCT06363994
- PirtobrutinibPhase 3 · NCT07784101 · NCT06252675 · NCT04662255 · NCT06522386 · NCT05833763 · NCT06553872 · NCT05990465 · NCT07207785 · NCT07684950 · NCT06263491 · NCT05529069
- Positron Emission TomographyPhase 3 · NCT06191887 · NCT06675123 · NCT07444710 · NCT05976763 · NCT07892027 · NCT06054776 · NCT03267433 · NCT07003295 · NCT04195633 · NCT01955499 · NCT05861050 · NCT05910801 · NCT07578077
- RituximabPhase 3 · NCT06572618 · NCT04002297 · NCT06496308 · NCT06564038 · NCT05495464 · NCT02427620 · NCT06854003 · NCT02682641 · NCT05635162 · NCT01415752 · NCT07444710 · NCT01695941 · NCT07225439 · NCT05976763 · NCT06522386 · NCT01479842 · NCT04115631 · NCT01318317 · NCT04913103 · NCT04626791 · NCT03523975 · NCT02972840 · NCT01661881 · NCT05004064 · NCT03710772 · NCT05951959 · NCT07855016 · NCT03267433 · NCT03863184 · NCT05025800 · NCT02339922 · NCT05864742 · NCT06839053 · NCT06846489 · NCT06363994 · NCT01880567 · NCT02446236 · NCT04765111 · NCT05283720 · NCT07691606 · NCT06084936 · NCT06263491 · NCT07578077 · NCT06136351
- Rituximab and Hyaluronidase HumanPhase 3 · NCT04626791 · NCT03267433
- RocbrutinibPhase 3 · NCT05716087 · NCT07377578
- SonrotoclaxPhase 3 · NCT07341191 · NCT06854003 · NCT06697184 · NCT06859008 · NCT06742996 · NCT06839053 · NCT07799220 · NCT05471843
- TocilizumabPhase 3 · NCT05833763 · NCT06084936 · NCT04007029
- VenetoclaxPhase 3 · NCT05753501 · NCT04939272 · NCT03872180 · NCT06496308 · NCT06522386 · NCT03523975 · NCT03710772 · NCT05951959 · NCT03946878 · NCT07719556 · NCT05864742 · NCT03824483 · NCT04855695 · NCT05861050 · NCT05910801 · NCT05529069
- zanubrutinibPhase 3 · NCT04002297 · NCT07261163 · NCT06029309 · NCT07341191 · NCT06854003 · NCT06697184 · NCT05635162 · NCT06341556 · NCT05976763 · NCT04662255 · NCT06859008 · NCT06742996 · NCT07377578 · NCT06504199 · NCT06839053 · NCT07799220 · NCT03824483 · NCT06136351
- [18F]F-RESCA-R8B4Phase 2 · NCT06852638
- [18F]F-RESCA-RCCB6Phase 2 · NCT06852638
- [18F]F-RESCA-RD06Phase 2 · NCT06852638
- [68Ga]Ga-NOTA-R8B4Phase 2 · NCT06852638
- [68Ga]Ga-NOTA-RD06Phase 2 · NCT06852638
- Acalabrutinib + R-CHOP standard of carePhase 2 · NCT07029737
- Acalabrutinib combination with RituximabPhase 2 · NCT07029737
- Acalabrutinib monotherapyPhase 2 · NCT07029737
- Acalabrutinib-rituximab in patients with untreated mantle cell lymphomaPhase 2 · NCT05214183
- ACP-196 (acalabrutinib)Phase 2 · NCT02213926
- Allogeneic Hematopoietic Stem Cell TransplantationPhase 2 · NCT04195633 · NCT00544115
- AraCPhase 2 · NCT03125642
- Autoleucel (Relmacabtagene Autoleucel)Phase 2 · NCT07077512
- Axicabtagene CiloleucelPhase 2 · NCT07892027 · NCT07763210
- BCL2 InhibitorPhase 2 · NCT07855016
- BCNUPhase 2 · NCT03125642
- BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)Phase 2 · NCT07199296
- BendamustinPhase 2 · NCT06136351
- Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibodyPhase 2 · NCT07206264
- bendamustine hydrochloridePhase 2 · NCT01479842 · NCT04115631 · NCT04913103 · NCT02153580
- BiopsyPhase 2 · NCT06191887 · NCT06675123 · NCT06859008 · NCT05861050 · NCT05910801
- Bone Marrow AspirationPhase 2 · NCT06675123 · NCT06859008 · NCT07910435 · NCT04195633 · NCT01955499 · NCT05910801
- bortezomibPhase 2 · NCT01415752 · NCT01695941 · NCT04626791 · NCT06656221
- Brexucabtagene AutoleucelPhase 2 · NCT07892027 · NCT06553872 · NCT07763210
- Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)Phase 2 · NCT07673367
- busulfanPhase 2 · NCT00544115
- Busulfan (BU)Phase 2 · NCT03674411
- Cancer Therapeutic ProcedurePhase 2 · NCT07285044
- CAR-TPhase 2 · NCT06504199
- CAR-T Cell TherapyPhase 2 · NCT07341191
- CC-99282Phase 2 · NCT05283720
- CD19-targeted Chimeric Antigen Receptor (CAR) T CellsPhase 2 · NCT04718883
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytesPhase 2 · NCT04484012
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)Phase 2 · NCT05281809
- ClonoSeq AssayPhase 2 · NCT06252675
- Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)Phase 2 · NCT05249959
- Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))Phase 2 · NCT05249959
- Core BiopsyPhase 2 · NCT07910435
- CyclophosphamidePhase 2 · NCT07569965 · NCT06026319 · NCT03676504 · NCT06564038 · NCT05495464 · NCT06191887 · NCT02427620 · NCT07024147 · NCT07444710 · NCT03277729 · NCT07892027 · NCT04223765 · NCT04545762 · NCT04626791 · NCT03710772 · NCT05665062 · NCT06253663 · NCT04792489 · NCT03125642 · NCT02153580 · NCT03842696 · NCT04195633 · NCT07763210 · NCT05283720 · NCT00544115 · NCT03622788 · NCT04007029 · NCT06002659
- Cyclophosphamide (CY)Phase 2 · NCT03674411
- CyclosporinePhase 2 · NCT04195633 · NCT00544115
- CytarabinePhase 2 · NCT02427620 · NCT06854003 · NCT07444710 · NCT02797470 · NCT04115631 · NCT04626791 · NCT01661881 · NCT03710772 · NCT06504199 · NCT07763210
- DexamethasonePhase 2 · NCT02427620 · NCT07444710 · NCT03710772 · NCT07763210
- DoxorubicinPhase 2 · NCT06564038 · NCT02427620 · NCT07444710
- Doxorubicin HydrochloridePhase 2 · NCT02427620 · NCT04626791 · NCT03710772
- Doxorubicin Hydrochloride [HCl]Phase 2 · NCT05283720
- EchocardiographyPhase 2 · NCT06191887 · NCT06054776 · NCT06357676
- Echocardiography TestPhase 2 · NCT04195633
- EpcoritamabPhase 2 · NCT05283720
- EtoposidePhase 2 · NCT02797470 · NCT03125642 · NCT02153580 · NCT00544115
- External Beam Radiation TherapyPhase 2 · NCT02494700
- FDG-Positron Emission Tomography and Computed Tomography ScanPhase 2 · NCT07910435
- FilgrastimPhase 2 · NCT01318317 · NCT04195633
- FludarabinePhase 2 · NCT07569965 · NCT06026319 · NCT03676504 · NCT06191887 · NCT07024147 · NCT07892027 · NCT04223765 · NCT04545762 · NCT05665062 · NCT06253663 · NCT04792489 · NCT04195633 · NCT03622788 · NCT06002659
- Fludarabine (FLU)Phase 2 · NCT03674411
- Fludarabine PhosphatePhase 2 · NCT05495464 · NCT03277729 · NCT02153580 · NCT00544115 · NCT04007029
- G-CSFPhase 2 · NCT03125642
- Gastrointestinal EndoscopyPhase 2 · NCT06839053
- Granulocyte Colony-Stimulating Factor (G-CSF)Phase 2 · NCT03674411
- HSCT with Non-TBI RegimenPhase 2 · NCT03314974
- HSCT with TBI RegimenPhase 2 · NCT03314974
- Ibrutinib 560 mgPhase 2 · NCT04802590
- ibrutinib and TisagenlecleucelPhase 2 · NCT04234061
- Immunomodulatory AgentPhase 2 · NCT07855016
- Iopofosine I 131 fractionated dosePhase 2 · NCT02952508
- Iopofosine I 131 multiple dosePhase 2 · NCT02952508
- Iopofosine I 131 single dosePhase 2 · NCT02952508
- Ixazomib CitratePhase 2 · NCT02339922
- KTE-X19Phase 2 · NCT06253663 · NCT06482684
- Linperlisib in combination with Obinutuzumab and VenetoclaxPhase 2 · NCT06324994
- LisaftoclaxPhase 2 · NCT07684950
- Lisaftoclax (APG-2575)Phase 2 · NCT07272499
- Low Dose Radiation TherapyPhase 2 · NCT04054167
- Lumbar PuncturePhase 2 · NCT05910801
- MelphalanPhase 2 · NCT02797470 · NCT03125642 · NCT03674411 · NCT00544115
- MethotrexatePhase 2 · NCT02427620 · NCT03710772 · NCT03842696 · NCT00544115
- MethylprednisolonePhase 2 · NCT07763210
- MGTA 456 InfusionPhase 2 · NCT03674411
- MosunetuzumabPhase 2 · NCT07910435
- Multigated Acquisition ScanPhase 2 · NCT06054776
- Mycophenolate MofetilPhase 2 · NCT04195633 · NCT00544115
- Mycophenolate Mofetil (MMF)Phase 2 · NCT03842696 · NCT03674411
- Mycophenolate SodiumPhase 2 · NCT04195633
- NatalizumabPhase 2 · NCT07892027
- NavitoclaxPhase 2 · NCT05864742
- NemtabrutinibPhase 2 · NCT06572618 · NCT05458297 · NCT07673367 · NCT03162536
- Neurologic ExaminationPhase 2 · NCT07910435
- OdronextamabPhase 2 · NCT03888105
- Orbital RadiationPhase 2 · NCT02494700
- orelabrutinib maintenancePhase 2 · NCT07199296
- PalbociclibPhase 2 · NCT02159755 · NCT03478514
- PemigatinibPhase 2 · NCT06300528
- Peripheral Blood Stem Cell TransplantationPhase 2 · NCT02797470 · NCT01318317 · NCT03125642 · NCT00544115 · NCT03622788
- Pirtobrutinib and rituximabPhase 2 · NCT07285590
- Polatuzumab vedotinPhase 2 · NCT04491370 · NCT07910435 · NCT04913103 · NCT05283720
- Polatuzumab, bendamustin und rituximabPhase 2 · NCT05868395
- Positron Emission Tomography and Computed Tomography ScanPhase 2 · NCT06572618
- PrednisonePhase 2 · NCT07444710 · NCT04626791 · NCT05283720
- R-CHOP chemotherapyPhase 2 · NCT04566887
- R-DHAOxPhase 2 · NCT04624958
- RBPhase 2 · NCT05245656
- RB/RBAC alternatingPhase 2 · NCT05245656
- Rituximab (R)Phase 2 · NCT07199296 · NCT07272499
- Sintilimab (PD-1 inhibitor)Phase 2 · NCT07077512
- sirolimusPhase 2 · NCT00544115
- tacrolimusPhase 2 · NCT00544115
- Tacrolimus (Tac)Phase 2 · NCT03674411
- TafasitamabPhase 2 · NCT06029309 · NCT07225439 · NCT05910801
- Therapeutic HydrocortisonePhase 2 · NCT07763210
- Total Body IrradiationPhase 2 · NCT03125642
- Total Body Irradiation (TBI)Phase 2 · NCT03674411
- Total-Body IrradiationPhase 2 · NCT04195633 · NCT00544115 · NCT03622788
- TreosulfanPhase 2 · NCT04195633
- TT-01488 TabletsPhase 2 · NCT07855016
- Tumor ImagingPhase 2 · NCT06252675
- UblituximabPhase 2 · NCT04783415
- UmbralisibPhase 2 · NCT04783415
- Venetoclax 10 MG Oral Tablet [Venclexta]Phase 2 · NCT04802590
- Venetoclax 100 MG Oral Tablet [Venclexta]Phase 2 · NCT04802590
- Venetoclax 50 MG Oral Tablet [Venclexta]Phase 2 · NCT04802590
- Venetoclax Oral ProductPhase 2 · NCT06558604
- VincristinePhase 2 · NCT06564038 · NCT02427620 · NCT07444710
- Vincristine SulfatePhase 2 · NCT02427620 · NCT03710772
- zamtocabtagene autoleucel (MB-CART2019.1)Phase 2 · NCT07569965 · NCT04792489
- Zanubrutinib and R-BACPhase 2 · NCT06427213
- Zanubrutinib and RCHOP/RDHAPPhase 2 · NCT06255704
- Zanubrutinib and RituximabPhase 2 · NCT04624958
- Zanubrutinib MaintenancePhase 2 · NCT04624958
- Zanubrutinib Oral CapsulePhase 2 · NCT06558604
- Zanubrutinib,ObinutuzumabPhase 2 · NCT06427213
- Zilovertamab vedotinPhase 2 · NCT05458297
- ZR2 RDHAPPhase 2 · NCT05992597
- 12-Day Production of Car-T CellsPhase 1/2 · NCT04186520
- 7×19-THEMIS CAR-T cellsPhase 1/2 · NCT07788118
- 8/12-Day Production of Car-T CellsPhase 1/2 · NCT04186520
- 8/12-Day Production of Cryopreserved Car-T CellsPhase 1/2 · NCT04186520
- Anti-Thymocyte GlobulinPhase 1/2 · NCT03622788
- AVM0703Phase 1/2 · NCT04329728
- AZD5492Phase 1/2 · NCT06542250
- Biopsy ProcedurePhase 1/2 · NCT07578077
- Blood and Marrow Transplant (BMT)Phase 1/2 · NCT03842696
- CAR20(NAP)-TPhase 1/2 · NCT06002659
- CarmustinePhase 1/2 · NCT02797470
- CD19.CAR T CellsPhase 1/2 · NCT03676504
- CD47 Antagonist ALX148Phase 1/2 · NCT05025800
- Chimeric Antigen Receptor T-Cell TherapyPhase 1/2 · NCT03277729 · NCT04007029
- Copanlisib HydrochloridePhase 1/2 · NCT04939272
- CTX112Phase 1/2 · NCT05643742
- Cytokine-treated Veto CellsPhase 1/2 · NCT03622788
- Dose Level 1, VNX-101Phase 1/2 · NCT06533579
- Dose Level 2, VNX-101Phase 1/2 · NCT06533579
- Dose Level 3, VNX-101Phase 1/2 · NCT06533579
- Dose Level 4, VNX-101Phase 1/2 · NCT06533579
- FDG-Positron Emission TomographyPhase 1/2 · NCT06357676
- Genetically Engineered Lymphocyte TherapyPhase 1/2 · NCT01318317
- GolcadomidePhase 1/2 · NCT07578077
- Lacutoclax+RocbrutinibPhase 1/2 · NCT07609862
- Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor CellsPhase 1/2 · NCT02797470
- LeukapheresisPhase 1/2 · NCT06191887 · NCT03277729
- PembrolizumabPhase 1/2 · NCT03153202
- PlerixaforPhase 1/2 · NCT01318317
- Prednisone (or equivalent)Phase 1/2 · NCT06564038
- SelinexorPhase 1/2 · NCT03147885
- SurovatamigPhase 1/2 · NCT06564038
- TacabrutidegPhase 1/2 · NCT05006716 · NCT05294731
- Tacrolimus (or cyclosporine)Phase 1/2 · NCT03842696
- VorinostatPhase 1/2 · NCT03842696
- ABBV-101Phase 1 · NCT05753501
- ABBV-291Phase 1 · NCT06667687
- AC676Phase 1 · NCT05780034
- Acalabrutinib in combination with BRPhase 1 · NCT02717624
- Acalabrutinib in combination with VRPhase 1 · NCT02717624
- AlisertibPhase 1 · NCT01695941
- Allogeneic NK cellsPhase 1 · NCT07225439
- anti-CD19 CAR-T cellsPhase 1 · NCT04545762
- Anti-CD19-CAR CMV-specific T-lymphocytesPhase 1 · NCT05432635
- APG-3288Phase 1 · NCT07424833
- ARC-02Phase 1 · NCT07691606
- Autologous BAFFR-targeting CAR T CellsPhase 1 · NCT06191887
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cellsPhase 1 · NCT02051257 · NCT01815749
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytesPhase 1 · NCT02051257 · NCT02153580
- autologous hematopoietic stem cells added to planned CAR TPhase 1 · NCT05887167
- BAFFR-CAR T cellsPhase 1 · NCT05370430
- Bone Marrow Aspiration and BiopsyPhase 1 · NCT06191887
- BTK InhibitorPhase 1 · NCT06675123
- BTK inhibitor PCI-32765Phase 1 · NCT01479842
- CAR.k.28Phase 1 · NCT04223765
- CD19-CAR-NK/TPhase 1 · NCT06464861
- CD19.20.22 CAR T cellsPhase 1 · NCT07168486
- CD19x22 CAR T CellsPhase 1 · NCT05098613
- CD22CART InfusionPhase 1 · NCT06340737
- CD79b-19 CAR T cellsPhase 1 · NCT06026319
- CemiplimabPhase 1 · NCT06022029
- CisplatinPhase 1 · NCT07444710
- CLIC-2201Phase 1 · NCT06208735
- Cyclophosphamide and Fludarabine lymphodepleting chemotherapyPhase 1 · NCT04049513
- DocirbrutinibPhase 1 · NCT05602363
- EXS73565Phase 1 · NCT06980116
- Fludarabine and CyclophosphamidePhase 1 · NCT07168486
- Fludarabine/cyclophosphamidePhase 1 · NCT07225439
- HDM2005 plus rituximab and lenalidomidePhase 1 · NCT07697339
- IKS03Phase 1 · NCT05365659
- Interleukin-2Phase 1 · NCT07225439
- JWCAR239Phase 1 · NCT07024147
- KeynatinibPhase 1 · NCT04807881
- L-Bcl-2 antisense oligonucleotidePhase 1 · NCT04072458
- LP-168Phase 1 · NCT04775745
- LTZ-301Phase 1 · NCT07121946
- LV20.19 CAR T cellsPhase 1 · NCT05990465
- Multi-peptide CMV-Modified Vaccinia Ankara VaccinePhase 1 · NCT05432635
- Myeloablative ConditioningPhase 1 · NCT05432635
- NKX019Phase 1 · NCT05020678
- NX-2127Phase 1 · NCT04830137
- NX-5948Phase 1 · NCT05131022
- ONM-501Phase 1 · NCT06022029
- PacritinibPhase 1 · NCT06675123
- PevonedistatPhase 1 · NCT03479268
- Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-LenPhase 1 · NCT07697339
- Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-LenPhase 1 · NCT07697339
- Rituximab plus lenalidomidePhase 1 · NCT07697339
- SC262Phase 1 · NCT06285422
- SC291Phase 1 · NCT05878184
- SGR-1505Phase 1 · NCT05544019
- Sonrotoclax, Zanubrutinib Combined with ObinutuzumabPhase 1 · NCT07548255
- STK-009Phase 1 · NCT05665062
- SYNCAR-001Phase 1 · NCT05665062
- SynKIR-310Phase 1 · NCT06544265
- Tazemetostat PillPhase 1 · NCT05934838
- WZTL002-1 (1928T2z CAR-T cells)Phase 1 · NCT04049513
Closest to patients
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationRoyal Perth Hospital · Perth, Australia + 170 more hospitalsPhase 3Results expected 2026
- A Long-term Extension Study of PCI-32765 (Ibrutinib)A Long-term Extension Study of PCI-32765 (Ibrutinib)Guangzhou, China + 128 more hospitalsPhase 3Results expected 2026
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionRituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionSaint Alphonsus Cancer Care Center-Baker City · Baker City, United States + 374 more hospitalsPhase 3Results expected 2027
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma.
25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma.
Journal of cancer research and clinical oncology
PubMed · PMID 31915915Trial result
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.
Clinical lymphoma, myeloma & leukemia
PubMed · PMID 32800518Publication
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
Oncotarget
PubMed · PMID 29765528
Find fellow researchers
Groups with active Mantle cell lymphoma work.
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
City Of Hope National Medical Center
Duarte, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Ludwig-Maximilians-Universität München
Munich, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
Memorial Sloan Kettering Cancer Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Dana-Farber Cancer Institute
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
LMU Klinikum
Munich, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
Moffitt Cancer Center
Tampa, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Weill Cornell Medicine
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The Ohio State University
Columbus, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Cleveland Clinic
Cleveland, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Hospital Clínic de Barcelona
Barcelona, Spain
Team details appear once the team leader joins.
Is this your team? Claim it